BioCentury
ARTICLE | Top Story

Enanta gains on Phase II HCV data

April 8, 2015 11:57 PM UTC

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) gained $3.71 (11%) to $36.38 on Wednesday after partner AbbVie Inc. (NYSE:ABBV) reported preliminary data from a Phase IIb trial of a once-daily oral combo of the biotech's ABT-493 plus ABT-530 to treat HCV.

AbbVie said the combination led to an SVR4 rate of 99% in 79 non-cirrhotic genotype 1 patients. The ribavirin-free regimen includes next-generation HCV NS3/4A protease inhibitor ABT-493 and HCV NS5A protein inhibitor ABT-530. ...